Merck Serono spins out sixth company - Calypso Biotech - to focus on gastrointestinal immunological disorders

5 March 2013

German drug major Merck KGaA’s (MRK: DE) subsidiary Merck Serono yesterday (March 4) announced the creation of Calypso Biotech, the sixth spin-off company resulting from its Entrepreneur Partnership Program (EPP).

Calypso Biotech was formed around Merck Serono's R&D portfolio in the field of inflammatory bowel diseases, targeting selected niche indications with high unmet medical needs. Merck Serono will invest 2.5 million euros ($3.2 million) as seed funding. Merck Serono Ventures will manage the investment and will be represented on the company's board of directors.

"We are pleased that Calypso Biotech will continue promising programs in inflammatory bowel diseases, while Merck Serono focuses its R&D efforts in other therapeutic areas," said Bernhard Kirschbaum, executive vice president and head of Global Research and Early Development at Merck Serono, adding: "Calypso Biotech has the portfolio, the expertise and the scientific network to build a unique translational medicine approach and to become a partner of choice in this therapeutic area."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK